These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10935705)

  • 21. Administration of anti-CD4 monoclonal antibody with intrathymic injection of alloantigen results in rat cardiac allograft tolerance.
    Arima T; Goss JA; Walp LA; Flye MW
    Surgery; 1995 Aug; 118(2):265-72; discussion 272-3. PubMed ID: 7638743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts.
    Binder J; Lehmann M; Graser E; Hancock WW; Watschinger B; Onodera K; Sayegh MH; Volk HD; Kupiec-Weglinski JW
    Transplantation; 1996 Mar; 61(5):804-11. PubMed ID: 8607187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX-38) anti-CD4 mAb plus intrathymic or intravenous donor alloantigen.
    Arima T; Lehmann M; Flye MW
    Transplantation; 1997 Jan; 63(2):284-92. PubMed ID: 9020332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thymus-dependent, anti-CD4-induced tolerance to rat cardiac allografts.
    Jaques BC; Ahmiedat H; Alastair Gracie J; Marshall HE; Middleton SE; Bolton EM; Bradley JA
    Transplantation; 1998 Nov; 66(10):1291-9. PubMed ID: 9846511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined monoclonal antibody therapy in experimental small bowel transplantation.
    Bowles MJ; Wood RF; Pockley AG
    Transplant Proc; 1996 Oct; 28(5):2510. PubMed ID: 8907926
    [No Abstract]   [Full Text] [Related]  

  • 26. The kinetics of tolerance induction by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus intravenous donor alloantigen administration.
    Motoyama K; Arima T; Yu S; Lehmann M; Flye MW
    Transplantation; 2000 Jan; 69(2):285-93. PubMed ID: 10670640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional, histological, and inflammatory changes in chronically rejecting small bowel transplants.
    de Bruin RW; Stein-Oakley AN; Kouwenhoven EA; Maguire JA; Jablonski P; Jin XJ; Dowling J; Thomson NM
    Transpl Int; 2000; 13(1):1-11. PubMed ID: 10743683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose, short-term treatment with anti-CD4 monoclonal antibody prolongs corneal allograft survival.
    Thiel MA; Takano T; Hawksworth N; Coster DJ; Williams KA
    Transplant Proc; 2001; 33(1-2):635-6. PubMed ID: 11266993
    [No Abstract]   [Full Text] [Related]  

  • 29. Short-term anti-CD4 plus anti-TNF-alpha receptor treatment in allogeneic small bowel transplantation results in long-term survival.
    Langrehr JM; Gube K; Hammer MH; Lehmann M; Polenz D; Pascher A; Volk HD; Reinke P
    Transplantation; 2007 Sep; 84(5):639-46. PubMed ID: 17876278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibody treatment (anti-CD4 and anti-interleukin-2 receptor) combined with cyclosporin A has a positive but not simple dose-dependent effect on rat renal allograft survival.
    Steinbrüchel DA; Koch C; Kristensen T; Kemp E
    Scand J Immunol; 1991 Nov; 34(5):627-33. PubMed ID: 1947798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerance to heart and kidney grafts induced by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) versus depleting anti-CD4 monoclonal antibody (OX-38) with donor antigen administration.
    Motoyama K; Arima T; Lehmann M; Flye MW
    Surgery; 1997 Aug; 122(2):213-9; discussion 219-20. PubMed ID: 9288125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence that long-term cardiac allograft survival induced by anti-CD4 monoclonal antibody does not require depletion of CD4+ T cells.
    Darby CR; Morris PJ; Wood KJ
    Transplantation; 1992 Sep; 54(3):483-90. PubMed ID: 1384184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IgG alloantibody responses to donor-specific blood transfusion in different rat strain combinations as a predictor of renal allograft survival.
    Wasowska B; Baldwin WM; Sanfilippo F
    Transplantation; 1992 Jan; 53(1):175-80. PubMed ID: 1370737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody.
    Ayliffe W; Alam Y; Bell EB; McLeod D; Hutchinson IV
    Br J Ophthalmol; 1992 Oct; 76(10):602-6. PubMed ID: 1358194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action.
    Hall BM; Pearce NW; Gurley KE; Dorsch SE
    J Exp Med; 1990 Jan; 171(1):141-57. PubMed ID: 2136906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 15AU81, a prostacyclin analog, enhances donor-specific hepatocytes to prolong the survival of rat heart but not small bowel allografts.
    Boyle MJ; Dumble LJ
    Cell Transplant; 1999; 8(5):543-8. PubMed ID: 10580348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of murine cardiac allograft rejection with gallium nitrate. Comparison with anti-CD4 monoclonal antibody.
    Orosz CG; Wakely E; Bergese SD; VanBuskirk AM; Ferguson RM; Mullet D; Apseloff G; Gerber N
    Transplantation; 1996 Mar; 61(5):783-91. PubMed ID: 8607184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolongation of rat cardiac allograft survival by a monoclonal antibody: anti-rat intercellular adhesion molecule-1.
    Kobayashi H; Miyano T; Yamataka A; Yamataka T; Yagita H; Eto H; Ligo Y; Tansyo S; Kojima Y; Tamatani T
    Cardiovasc Surg; 1993 Oct; 1(5):577-82. PubMed ID: 7915626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with monoclonal antibodies to ICAM-1 and LFA-1 in rat heart allograft rejection.
    Brandt M; Steinmann J; Steinhoff G; Haverich A
    Transpl Int; 1997; 10(2):141-4. PubMed ID: 9090001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for maintenance of tolerance to alloantigen in vivo in anti-CD4 treated recipients.
    Hamano K; Rawsthorne MA; Bushell AR; Morris PJ; Wood KJ
    Transplantation; 1996 Sep; 62(6):856-60. PubMed ID: 8824489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.